Category: 3. Business

  • Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population

    Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population

    Combining darolutamide (Nubeqa) with androgen deprivation therapy (ADT) showed improvements in efficacy vs placebo plus ADT among patients with metastatic hormone-sensitive prostate cancer (HSPC) who were 75 years or older, according to subgroup findings from the phase 3 ARASENS trial (NCT02799602) published in European Urology Oncology.1

    Among patients who were 75 years or older, the median overall survival (OS) was not reached (NR; 95% CI, 45.4-NR) in the darolutamide arm vs 42.0 months (95% CI, 33.8-48.9) in the placebo arm (HR, 0.61; 95% CI, 0.41-0.91). In each respective arm, the median time to metastatic castration-resistant prostate cancer (CRPC) was NR (95% CI, 36.0-NR) vs 19.4 months (95% CI, 14.0-24.8; HR, 0.42; 95% CI, 0.28-0.64), and the median time to initiation of subsequent antineoplastic treatment was NR (95% CI, NR-NR) vs 24.9 months (95% CI, 20.0-34.0; HR, 0.35; 95% CI, 0.22-0.54).

    In a population of patients who were younger than 75, data showed a median OS that was NR (95% CI, NR-NR) with the darolutamide regimen and NR (95% CI, 45.0-NR) with the placebo combination (HR, 0.70; 95% CI, 0.58-0.84). Additionally, the median time to CRPC was NR (95% CI, NR-NR) vs 17.3 months (95% CI, 16.4-19.5) in each arm (HR, 0.35; 95% CI, 0.30-0.43). Investigators also noted a median time to initiation of subsequent antineoplastic therapy of NR (95% CI, NR-NR) vs 25.3 months (95% CI, 22.4-29.5) with each regimen (HR, 0.40; 95% CI, 0.34-0.48).

    “In patients aged [75 or older] in the ARASENS trial, darolutamide demonstrated improved efficacy vs placebo and favorable safety, consistent with the findings in patients aged [younger than 75],” lead study author Joan Carles Galceran, MD, PhD, a medical oncologist in the Department of Oncology at Hospital Universitari Vall d’Hebron in Barcelona, Spain, wrote with coauthors in the publication.1 “Thus, darolutamide and ADT with docetaxel can be considered a standard of care for patients with [metastatic] HSPC regardless of age.”

    In the international phase 3 ARASENS trial, patients were randomly assigned to receive darolutamide at 600 mg orally twice daily or matched placebo plus ADT and docetaxel. As part of this subgroup analysis, investigators assessed outcomes in patients who were younger than 75 (n = 1086) or 75 years and older (n = 219).

    The trial’s primary end point was OS. Secondary end points included treatment-emergent adverse effects (TEAEs), time to CRPC, time to pain progression, time to initiation of subsequent antineoplastic therapy, and time to worsening of disease-related physical symptoms.2

    Patients 18 years and older with cytologically or histologically confirmed adenocarcinoma of the prostate and metastatic disease were eligible for enrollment on the trial. Additional eligibility criteria included having an ECOG performance status of 0 or 1 and adequate bone marrow, liver, and renal function.

    Investigators noted similar baseline disease and demographic features across the darolutamide and placebo arms in both age subgroups, although ongoing comorbidities were more frequent in patients who were 75 years or older. The most frequent prior and ongoing comorbidity types in patients who were younger than 75 or 75 and older, respectively, included vascular (55% vs 67%), musculoskeletal or connective tissue (42% vs 42%), and metabolism or nutrition (35% vs 43%).

    Among patients 75 years and older in the darolutamide and placebo arms, 99% and 99% from each group had any-grade TEAEs, the most common of which included neutropenia (43% vs 46%), fatigue (33% vs 36%), and peripheral edema (30% vs 35%). Grade 3/4 TEAEs occurred in 74% vs 70% of each arm, with the most common including neutropenia (40% vs 41%) and febrile neutropenia (14% vs 9.7%).

    Among those who were younger than 75, 99.6% in the darolutamide arm and 99.0% of the placebo arm had TEAEs of any grade; the most common types of toxicity in each arm included alopecia (43% vs 42%), neutropenia (38% vs 37%), and fatigue (33% vs 32%). Grade 3/4 TEAEs were reported in 65% and 62% of each arm, with the most common toxicities including neutropenia (33% vs 33%) and febrile neutropenia (6.6% vs 6.9%).

    References

    1. Carles J, Tombal B, Hussain M, et al. Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer: a subgroup analysis of the phase 3 ARASENS trial. Eur Urol Oncol. 2025l4:S2588-9311(25)00255-X. doi:10.1016/j.euo.2025.10.001
    2. Darolutamide in addition to standard androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer (ARASENS). ClinicalTrials.gov. Updated April 16, 2024. Accessed November 20, 2025. https://tinyurl.com/3f5h3a7k

    Continue Reading

  • Evaluating Valuation After Strong Share Price Growth

    Evaluating Valuation After Strong Share Price Growth

    Westgold Resources (ASX:WGX) has shown solid share price growth over the past quarter, with shares climbing nearly 69% in that time. Investors are likely watching closely as the company continues to ride this positive momentum.

    See our latest analysis for Westgold Resources.

    Looking beyond the past quarter, Westgold Resources’ momentum stands out, with an 88.6% share price return year-to-date and a 92.1% total shareholder return over the last year. That kind of sustained outperformance hints that investors are starting to recognize its progress and growth potential, particularly after management’s recent positive updates.

    If this kind of strong momentum has you wondering what other opportunities are out there, now’s a great chance to broaden your scope and discover fast growing stocks with high insider ownership

    With shares up strongly and investor optimism running high, the key question now is whether Westgold’s current price truly reflects the company’s fundamentals or if there remains untapped value for those considering a buy.

    Westgold Resources’ most widely followed valuation narrative suggests the shares have room to run, as its fair value estimate sits well above the latest close. Market optimism is high, yet the reasoning behind this impressive valuation hinges on specific developments that analysts believe could be major game changers.

    Extensive mine and infrastructure upgrades, specifically at Bluebird-South Junction, Beta Hunt, and the Higginsville plant, are expected to materially lift volumes, grades, and operational efficiency over FY ’26. These factors support net margin expansion as higher-quality ore feeds, cost savings, and productivity gains take hold.

    Read the complete narrative.

    Think this is just another bullish take? The calculation behind this upside view leans on projected gains in margins and some aggressive profit forecasts for the next few years. Wondering how analysts arrive at a price nearly a fifth above today’s? Find out the forecasted numbers and the financial logic driving this bold valuation.

    Result: Fair Value of $6.83 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent low ore grades or failure to deliver expected cost reductions could quickly undermine these bullish forecasts and slow Westgold’s upward momentum.

    Find out about the key risks to this Westgold Resources narrative.

    While the fair value estimate sees upside, a look at the price-to-earnings ratio tells a starkly different story. Westgold trades at 148.2 times earnings, which is far above the Australian metals and mining industry’s 19.6x and its peers’ average of 27.5x. Even compared to the fair ratio of 36.2x, the current multiple stands out as steep. This raises the risk the shares might be priced for perfection. Are the expectations built into this premium justified, or could sentiment turn sharply if ambitions are not met?

    See what the numbers say about this price — find out in our valuation breakdown.

    ASX:WGX PE Ratio as at Nov 2025

    If you want to take a different perspective or have your own insights to test, it takes less than three minutes to shape your version of the narrative. Do it your way

    A great starting point for your Westgold Resources research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

    Seize your chance to uncover untapped opportunities beyond Westgold. Don’t give other investors the first move. Fresh ideas could put you ahead of the market.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include WGX.AX.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Klarna Group’s Stock Slides 24% as New Payment Partnerships Spark Valuation Debate

    Klarna Group’s Stock Slides 24% as New Payment Partnerships Spark Valuation Debate

    • Wondering if Klarna Group might be undervalued, or if the recent market buzz is masking hidden risks? You are definitely not alone, and now is the perfect time to dig deeper.

    • In the last month, Klarna Group’s stock has dropped by 24.3%, and it is down a striking 36.6% year-to-date. This performance puts the company firmly on the radar of both contrarian investors and those watching for warning signs.

    • Recently, Klarna has been making headlines with announcements about expanding its payment solutions and forming new partnerships with major retailers. These developments are grabbing investor attention and adding to the stock’s volatility. They could indicate new growth opportunities, but they also raise questions about the sustainability of Klarna’s current strategy and how the market is reacting to these bold steps.

    • According to our valuation checklist, Klarna Group is undervalued in only 1 out of 6 checks right now. Next, we will break down what the numbers actually say and then show you a smarter way to really understand what “fair value” means for stocks like Klarna.

    Klarna Group scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    The Excess Returns valuation model examines how effectively Klarna Group generates returns above its cost of equity, essentially measuring how much real value is created for shareholders after accounting for the capital invested in the business. This model is especially relevant for financial firms, where return on invested capital and sustainable growth are key drivers of actual intrinsic value.

    Looking at Klarna Group’s latest data, the company has a Book Value of $6.32 per share and is projected to achieve a Stable Earnings Per Share (EPS) of $0.27, based on weighted future Return on Equity estimates from 8 different analysts. The estimated Cost of Equity stands at $0.64 per share. However, the calculated Excess Return is negative, at $-0.37 per share. Klarna’s average Return on Equity is a modest 3.37%, with a forecasted Stable Book Value of $8.09 per share, as estimated by 5 analysts.

    When applied, the Excess Returns model implies an intrinsic value that is significantly below Klarna’s current share price. The model indicates the stock is overvalued by 15,675.1%. This reflects that Klarna is struggling to generate returns high enough to justify its capital cost and market valuation.

    Result: OVERVALUED

    Our Excess Returns analysis suggests Klarna Group may be overvalued by 15675.1%. Discover 926 undervalued stocks or create your own screener to find better value opportunities.

    Continue Reading

  • From milking stalls to mobile apps: UN-supported project powers rural revival in Indonesia

    From milking stalls to mobile apps: UN-supported project powers rural revival in Indonesia

    Members of the South Bandung Farming Cooperative (KPBS) have recorded a 38 per cent increase in productive loans and a 43 per cent rise in sales volumes over the past two years, following the introduction of a new business app.

    “Easier access to financing means higher loan volumes, which in turn means more cattle and higher income for our farmers,” said Head of KBPS Aun Gunawan. “This is how financial inclusion leads to improved livelihoods.”

    UN Indonesia/Miklos Gaspar

    Dairy farmers in Indonesia are using a new business-focused app which is helping them to boost sales.

    Founded in 1969, KPBS has 5,000 members and produces 70,000 tons of milk a day. The cooperative operates its own dairy plant, using around 15 per cent of its milk production to manufacture yoghurt and mozzarella cheese, while the remainder is sold to dairy companies in the region. 

    In addition, the cooperative runs a hospital, veterinary service, and a bank—all designed to support members and enhance their well‑being and competitiveness.

    Holistic and healthy

    “We take a holistic approach, and for us it is all about health—not only the health of farmers and their cattle, but also financial health,” Mr Gunawan explained to the heads of United Nations agencies in Indonesia, who visited KPBS as part of their annual Leadership Dialogue on shaping the UN’s trajectory in the country.

    The International Labour Organization (ILO) is now supporting the cooperative in implementing this vision, leveraging digitization to strengthen financial inclusion. The project is implemented in cooperation with the Indonesian Financial Services Authority (OJK) and the Coordinating Ministry of Economic Affairs.

    A worker checks the pH of semi-fermented milk as part of the cheese-productioin process.

    UN Indonesia/Miklos Gaspar

    A worker checks the pH of semi-fermented milk as part of the cheese-productioin process.

    “KPBS was already a strong, well‑managed business before our involvement,” said Simrin Singh, ILO Country Director for Indonesia and Timor‑Leste. “The tools we have provided have catalyzed further improvements and enhanced livelihoods.”

    Through the Enterprise Resource Planning (ERP) system business app – introduced by the ILO under a project funded by the Government of Switzerland – farmers can now track their income and expenses, including the cost of fodder provided by the cooperative. 

    They also have 24/7 access to the cooperative’s veterinarians, who can reach farms within 30 minutes. 

    The app records individual animals’ veterinary data, including vaccination schedules, enabling milk collection points to segregate milk from recently vaccinated cows. If mixed with regular milk, such milk could reduce the day’s overall quality—and therefore the selling price.

    Higher volume, better price

    “These practical improvements have contributed not only to higher volumes but also to better prices per litre sold,” Mr Gunawan said.

    The most significant impact, however, has been improved access to finance. The cooperative has operated its own bank since 1993 to provide farmers with credit. 

    With the ERP system, loan applications have become simpler and more accessible, Ms Singh explained. The bank can now view farmers’ financial data – income, liquidity, and outstanding debt – directly through the system, resulting in a higher rate of approved applications.

    Applications have also increased. With the integrated ERP tool, farmers no longer need to travel and queue to complete forms; they can apply directly through the app, where their financial history is already recorded and available to the lending team. 

    Dairy cows feed at a farm in Pangalengan, in West Jave, Indonesia.

    UN Indonesia/Miklos Gaspar

    Dairy cows feed at a farm in Pangalengan, in West Jave, Indonesia.

    “This may sound like a matter of convenience, but it is far more than that,” said dairy farmer Encih Mintarsih. “Farmers cannot easily leave their cattle for half a day, let alone multiple times, to submit an application that may not even be approved. 

    “Now we can apply online and spend our time productively. That makes us far more likely to pursue financing,” she added.

    Towards food self‑sufficiency

    Programmes like this have broader national relevance: strengthening domestic food production and self‑reliance is a top priority for the Government of Indonesia. 

    The country currently imports around 80 per cent of its dairy products. Enhancing the productivity and competitiveness of local milk producers contributes directly to national self‑sufficiency goals.
    It also provides a model for inclusive rural economic growth.

    “In an upper‑middle‑income country like Indonesia, the digital transformation of the economy and improved access to finance are essential for progressing toward high‑income status,” said Gita Sabharwal, UN Resident Coordinator in Indonesia. “For this reason, in close consultation with the Government, digitalization and access to finance are key priorities of the new cooperation framework between the UN and Indonesia.”

    The United Nations Sustainable Development Cooperation Framework (UNSDCF), signed in August 2025 and aligned with the SDGs and Indonesia’s national development agenda, outlines how the UN will contribute to three transformative outcomes in the country, including Economic and Digital Transformation. 

    “This outstanding programme by the ILO demonstrates how the UN can complement the Government’s efforts to accelerate inclusive development using modern technology,” Ms Sabharwal said.

    The project contributes directly to OJK’s Rural Bank Transformation Blueprint, strengthens the inclusive financial ecosystem model, and supports the efforts of the National Committee on Financial Literacy and Inclusion to improve financial literacy and inclusion. It also aligns with national priorities to digitize small and medium-sized enterprises (SMEs) and boost productivity through digital tools.

    “In Indonesia, 90 per cent of jobs are created by SMEs – so improving their competitiveness is critical to ensuring decent work,” Ms Singh said. 

    The intent is for this approach to be rolled out more widely across the country.

    What advice does Mr Gunawan have for other cooperatives and policymakers? “Show farmers clear and tangible benefits, and they will quickly adopt digital technologies,” he said. 

    “Buzzwords like ‘digitization’ and ‘financial inclusion’ must be translated into their daily reality – just as we have done here with the support of the ILO and the UN.”

    Continue Reading

  • Chinese pharma is on the cusp of going global – The Economist

    1. Chinese pharma is on the cusp of going global  The Economist
    2. China Ramps Up Experiments on Animals to Help Win Biotech Race  Bloomberg.com
    3. Why China’s pharma market is now a consumer game  Healthcare Asia Magazine
    4. China’s pharma growth shifts from drugs to high-tech manufacturing  Healthcare Asia Magazine
    5. China’s licensing boom reshapes global pharma power  Healthcare Asia Magazine

    Continue Reading

  • Bayer reports positive results for blood thinner after 2023 setback

    Bayer reports positive results for blood thinner after 2023 setback

    BERLIN, Nov 23 (Reuters) – German pharma company Bayer (BAYGn.DE), opens new tab reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.

    In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.

    Sign up here.

    Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.

    Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.

    Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) – more than any of its other drugs.

    At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.

    ($1 = 0.8687 euros)

    Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading

  • UK and Scottish ministers to hold rival Mossmorran summits

    UK and Scottish ministers to hold rival Mossmorran summits

    Phil Sim and

    Megan Bonar,BBC Scotland

    BBC Douglas Alexander, wearing a navy suit and burgundy tie, sitting on a wall next to Kate Forbes who is wearing a dark blazer and pink top. Behind them is a bridge and water.BBC

    Douglas Alexander and Kate Forbes have both planned separate summits

    The Scottish and UK governments have invited each other to meetings amid confusion over efforts to support the closure-threatened chemical plant at Mossmorran.

    Deputy first minister Kate Forbes is to meet with owners ExxonMobil at the Fife ethylene site on Tuesday, aiming to set up a taskforce alongside Scottish Enterprise.

    But Scottish Secretary Douglas Alexander has called for Forbes to instead join a group led by Fife Council, and to attend a meeting of local business leaders set for Monday.

    The plant is due to close in February, with 179 directly employed jobs at risk alongside those of 250 contractors.

    Getty Images A general view of the ExxonMobil site. There are several tall metal cylinders jutting into a grey sky.Getty Images

    The Fife plant is due to close in February

    Forbes was first to announce a summit, saying on Sunday morning that she would visit the plant alongside Scottish Enterprise while inviting groups including unions, the council and the UK government to meet on Tuesday.

    Ms Forbes said: “Our immediate priority is to explore way to retain employment at the site and support the workforce through this period of uncertainty.

    “In the meantime, this summit will bring together all the key stakeholders and I am keen that we consider every possible option to support the workforce at this distressing time.”

    Alexander then wrote to her saying she should get on board with a council-led taskforce instead, saying there should be a “Team Scotland” approach to supporting the workforce.

    Alexander said it was an incredibly difficult time for workers and he hoped the government will attend the meeting.

    He said: “I look forward to meeting Fife Council tomorrow to discuss how working together we can all best support the workers, mitigate the impact of the closure on the wider Fife economy, and look at alternative uses for the site.

    “It is right that the response is focussed on local needs, and has clear governance structures.”

    Map showing Mossmorran plant in relation to Edinburgh and Kirkcaldy

    Staff were told about plans to cease operations at the Fife site during a meeting on Tuesday morning, where details of financial packages and retraining and relocation support were discussed.

    There is a possibility of 50 staff transferring to the Fawley Petrochemical Complex 480 miles (780km) away in Hampshire.

    Contractors at the plant told BBC Scotland News that the closure announcement came as a shock.

    The site has produced ethylene for about 40 years through a process known as thermal or steam cracking.

    Exxon Mobil said it had been seeking a buyer for several months and it would clean up and then demolish the site once production ends.

    Banner saying Analysis, by Phil Sim, Political correspondent

    This bizarre display of synchronised summitry would almost be funny if there weren’t hundreds of jobs on the line.

    The Scottish and UK governments actually do have a history of working together on issues like this, having jointly committed hundreds of millions of pounds to efforts to secure a green future for Grangemouth.

    However, in this case they seem to be talking past each other and communicating by press release.

    Fife is a key battleground between the SNP and Labour, and both are clearly keen to be seen to stand up for local workers. They both immediately announced they would set up taskforces, apparently without coordinating their efforts.

    Ultimately this is a serious enough issue that following this flurry of meetings they will surely get their ducks in a row and figure out a way to cooperate.

    But Grangemouth is also a reminder that if the private company behind the plant decide it’s shutting, there’s little that any government can do to change that, short of stumping up vast sums to nationalise it.

    Finding alternative employment and supporting the workforce into new roles is going to end up being the true test of the “just transition” that is so often talked about.

    Continue Reading

  • What Maplebear’s New Partnerships Mean for Its Current Share Price in 2025

    What Maplebear’s New Partnerships Mean for Its Current Share Price in 2025

    • Ever wondered if Maplebear stock is trading at a price that’s a true bargain, or if there’s more risk than meets the eye? You’re not alone. We’re about to break it all down for you.

    • Maplebear’s share price has seen subtle shifts lately. It ticked up 2.7% over the last month, even after a slight dip of 2.1% in the past week, and it’s down 6.6% since the start of the year.

    • Headlines surrounding Maplebear have brought both excitement and fresh questions as investors digest both opportunity and uncertainty. Recent news has focused on the company’s evolving partnerships and ambitious plans for expanding its on-demand model, which have caught the attention of market watchers and may be helping to shape short-term price trends.

    • On our 6-point valuation scale, Maplebear clocks in at a 2 out of 6, signaling it’s undervalued on two key measures. We’ll unpack what each approach reveals in detail. Make sure to stick around for a smarter way to size up the company’s value at the end of the article.

    Maplebear scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    A Discounted Cash Flow (DCF) valuation model estimates what a company is really worth by projecting its future free cash flows and discounting them back to today’s value. This helps investors cut through short-term market noise and focus on the business’s underlying ability to generate cash.

    For Maplebear, the DCF uses the 2 Stage Free Cash Flow to Equity approach. Currently, Maplebear generates Free Cash Flow (FCF) of $878.8 Million. Analyst estimates project FCF to increase to $1,080.88 Million by 2029, with further growth anticipated in the following years based on modeled extrapolations.

    Simply Wall St’s DCF analysis values Maplebear’s stock at $94.63 per share. With the current market price reflecting a 57.5% discount to this intrinsic value, the analysis indicates that Maplebear is significantly undervalued according to future cash flow projections.

    Result: UNDERVALUED

    Our Discounted Cash Flow (DCF) analysis suggests Maplebear is undervalued by 57.5%. Track this in your watchlist or portfolio, or discover 926 more undervalued stocks based on cash flows.

    CART Discounted Cash Flow as at Nov 2025

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Maplebear.

    The Price-to-Earnings (PE) ratio is a popular metric for valuing profitable companies like Maplebear because it reflects how much investors are willing to pay for each dollar of earnings. It balances market sentiment with the company’s demonstrated ability to generate profits, making it solid for gauging value in established, earnings-generating firms.

    Continue Reading

  • How Recent Shifts Are Reshaping the Unisys Growth Story According to Analysts

    How Recent Shifts Are Reshaping the Unisys Growth Story According to Analysts

    Unisys has seen its Fair Value Estimate reduced from $5.75 to $5.25. This reflects a modest shift in analyst sentiment amid evolving market conditions. The unchanged discount rate and flat revenue growth forecast highlight continued uncertainty, with industry headwinds weighing against optimistic long-term projections. As investor opinions remain divided, readers are encouraged to follow along for the latest strategies to track how Unisys’s story develops in the coming months.

    Stay updated as the Fair Value for Unisys shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Unisys.

    Recent analyst coverage of Unisys reflects a divided outlook for the company, with varying opinions on its valuation, growth trajectory, and management’s execution strategy.

    🐂 Bullish Takeaways

    • Needham initiated coverage with a Buy rating and a $6 price target. The firm highlights Unisys’s global reach and improving operational environment.

    • There is potential for margin expansion, and the planned removal of Unisys’s U.S. pension plan within five years is seen as a catalyst for a re-rating of the shares, as it would eliminate the pension overhang.

    • Analysts recognize Unisys’s opportunity to return to growth as cyclical pressures ease. Cost control and execution are seen as pivotal strengths.

    🐻 Bearish Takeaways

    • Jefferies initiated Unisys with a Hold rating and a $4 price target. The firm notes stable revenues but would prefer to see a longer period of sustained execution before becoming more positive on the shares.

    • Jefferies remains cautious, citing the need for consistent performance and expressing hesitancy to recommend the stock until execution proves reliable over time.

    Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

    NYSE:UIS Community Fair Values as at Nov 2025
    • Unisys lowered its full-year 2025 earnings guidance, now expecting constant currency revenue to decline between 4.0 percent and 3.0 percent due to revised outlooks across both its Legacy & Services and Ex-Legacy & Services segments.

    • The company reported a $55 million goodwill impairment for the third quarter ended September 30, 2025, up from $39.1 million a year earlier. This reflects increased challenges within certain business units.

    • Unisys was chosen by the European Commission to lead the EUCybersafe Consortium, providing cybersecurity services to 71 European Union institutions and agencies as part of a four-year contract focused on threat management and incident response.

    • The company expanded its Sustainable Workplace solution in collaboration with Appspace. This initiative aims to deliver advanced space management and real-time workplace data for office environments worldwide.

    Continue Reading

  • No recession risk for US economy as a whole, Bessent tells NBC – Reuters

    1. No recession risk for US economy as a whole, Bessent tells NBC  Reuters
    2. Treasury secretary says there won’t be a recession in 2026  NBC News
    3. Bessent: Raising the Debt Ceiling by July Is Essential to Prevent Market Turmoil  Bitget
    4. Bessent says inflation ‘has nothing to do with tariffs’ as U.S. rolls them back: Full interview  Yahoo
    5. Bessent: Interest rate sensitive sectors are in recession, but confident about 2026 growth prospects  MarketScreener

    Continue Reading